We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio
Unlock the market timeline & signal feed
1,377 signals in the last 90 days.
The order this company entered each market — oldest to newest
68 active postings
19 active postings
Sign up to see the full signal feed
How AstraZeneca's international expansion compares to its competitors
AstraZenecaYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 AstraZenecaYou | 61 | 0 | +250% | 1.3k | 51 |
Senior Director Compliance and Legal Services
View postingWilmington, DE · today
Senior Scientist in vitro ADME
View postingGothenburg, Västra Götaland County, Sweden · Full-time · yesterday
BISO - RDU
View postingBarcelona, Catalonia, Spain · yesterday
Consulta Pública
Active
Consulta Pública
Active
Tomorrow’s healthcare: united by purpose, powered by real-world data and AI
ActiveAstraZeneca presents over 85 abstracts at ASCO 2026, including EMERALD-3 trial results for early-stage liver cancer and CARES study on anselamimab for AL amyloidosis, alongside breast cancer data.
Ascentage Pharma presented updated efficacy and safety data for Olverembatinib (HQP1351) as second-line CML-CP treatment at ASCO 2026, showing 91.3% CCyR and 60.9% MMR at 24 cycles with manageable safety profile.
Ascentage Pharma presented Phase Ib data at ASCO 2026 showing olverembatinib combined with blinatumomab achieved 91% complete response rate in Ph+ BCP-ALL or CML-LBP patients with favorable safety profile.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about AstraZeneca's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
